Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05885-1 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Chao-Wei Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hepatectomy, Autoimmune Diseases. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, Linkou, Ministry of Science and Technology, Taiwan, R.O.C..
Abstract (Originalsprache)
Background
Patients with autoimmune diseases (AD) generally carry an increased risk of developing cancer. However, the effect of AD in hepatocellular carcinoma (HCC) patients receiving surgical treatment is uncertain. The present study aimed to investigate the potential influence of AD on the survival of HCC patients undergoing hepatectomies.
Methods
Operated HCC patients were identified from the Chang Gung Research Database, and the survival outcomes of HCC patients with or without AD were analyzed ad compared. Cox regression model was performed to identify significant risk factors associated with disease recurrence and mortality.
Results
From 2002 to 2018, a total of 5532 patients underwent hepatectomy for their HCC. Among them, 229 patients were identified to have AD and 5303 were not. After excluding cases who died within 30 days of surgery, the estimated median overall survival (OS) was 43.8 months in the AD (+) group and 47.4 months in the AD (–) group ( P = 0.367). The median liver-specific survival and disease-free survival (DFS) were also comparable between the two groups. After Cox regression multivariate analysis, the presence of AD did not lead to a higher risk of all-cause mortality, liver-specific mortality, or disease recurrence.
Conclusion
Our study demonstrated that autoimmune disease does not impair the OS and DFS of HCC patients undergoing liver resections. AD itself is not a risk factor for tumor recurrence after surgery. Patients eligible for liver resections, as a result, should be considered for surgery irrespective of the presence of AD. Further studies are mandatory to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan.
- College of Medicine, Chang Gung University, Guishan, Taoyuan, Taiwan.
- Graduate Institute of Clinical Medical Sciences, Chang Gung University, Guishan, Taoyuan, Taiwan.
- Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Taoyuan Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan.
- School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Guishan, Taoyuan, Taiwan.
- Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, Tu-Cheng, New Taipei City, Taiwan.
Förderung
- Chang Gung Memorial Hospital, Linkou
- Ministry of Science and Technology, Taiwan, R.O.C.
Zitieren
APA
Lee, C. W., Chen, H. Y., Tsai, P. H., Lee, W. C., Wang, C. C., Yu, M. C., Chen, C. W., Lin, P. T., Chen, B. H., Wang, S. F., Chai, P. M., & Tsai, H. I. (2024). Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05885-1
Vancouver
Lee CW, Chen HY, Tsai PH, Lee WC, Wang CC, Yu MC, et al. Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05885-1
BibTeX
@article{Lee2024,
author = {Lee, Chao-Wei and Chen, Hsing-Yu and Tsai, Ping-Han and Lee, Wei-Chen and Wang, Chih-Chi and Yu, Ming-Chin and Chen, Chun-Wei and Lin, Po-Ting and Chen, Bo-Huan and Wang, Sheng-Fu and Chai, Pei-Mei and Tsai, Hsin-I},
title = {Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05885-1}
}
EUVIMED